Findings reveal ALKBH3 limits cell death in cardiomyocytes after ischemia/reperfusion, suggesting new therapeutic approaches.
These findings identify the ALKBH3/ZBED6/STAT1/AIM2 signalling axis that epitranscriptomically breaks cardiomyocyte PANoptosis, highlighting a tractable therapeutic target that limits cell death and improves myocardial outcomes after I/R.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: